戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nge, 0 to 15.5 years), 132 died (67 received dexrazoxane).
2  randomly assigned to an arm with or without dexrazoxane.
3 tinal RT, dexrazoxane, or mediastinal RT and dexrazoxane.
4 stinal RT, and 307 patients (12.0%) received dexrazoxane.
5 steosarcoma treated with doxorubicin without dexrazoxane.
6  is both selective for TOP2B and superior to dexrazoxane.
7 teosarcoma who all received doxorubicin with dexrazoxane.
8 gned patients to doxorubicin with or without dexrazoxane.
9  effect in the presence of the iron chelator dexrazoxane.
10  dose of doxorubicin preceded by 300 mg/m(2) dexrazoxane.
11 ved in patients randomly assigned to receive dexrazoxane.
12 l because of concerns of tumor protection by dexrazoxane.
13 21-0.93) but not for those who also received dexrazoxane (-0.41, -0.88 to 0.06; 0.15, -0.20 to 0.51).
14                                              Dexrazoxane: (1) The use of dexrazoxane is not routinely
15                                 In contrast, dexrazoxane (10 micromol/L), known clinically to limit a
16 n alone than in the 31 patients who received dexrazoxane (-2.03 v -0.24; P </= .001).
17  doses of doxorubicin 30 mg/m2/d for 2 days, dexrazoxane 300 mg/m2/d for 2 days, and cyclophosphamide
18 three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediate
19 er, there was a suggestion of lower TRM with dexrazoxane (5.7% v 12.7%; P = .068).
20 hen combined with doxorubicin (60 mg/m2) and dexrazoxane (600 mg/m2), paclitaxel given as a 3-hour in
21 in (66 analysed) and 105 to doxorubicin plus dexrazoxane (68 analysed).
22                                              Dexrazoxane, a drug that attenuates doxorubicin-induced
23                                              Dexrazoxane, a free-radical scavenger, may protect the h
24                                              Dexrazoxane administration was associated with superior
25 ntagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta,
26                                              Dexrazoxane also was not significantly associated with d
27              Hence, we evaluated a series of dexrazoxane analogues and found that their cardioprotect
28 one were more likely than those who received dexrazoxane and doxorubicin to have elevated troponin T
29 up and 82 of 105 patients in the group given dexrazoxane and doxorubicin.
30                                              Dexrazoxane and Mito-T (4) ameliorated doxorubicin-induc
31 s were noted between the group that received dexrazoxane and the group that did not (P = .66).
32 port found an association between the use of dexrazoxane and the risk of developing secondary maligna
33 ma, who received doxorubicin with or without dexrazoxane, and a nonrandomized trial of patients with
34 OP2B in cardiomyocytes more efficiently than dexrazoxane, and showed the highest cardioprotective eff
35           Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage t
36                           Further studies on dexrazoxane are warranted to confirm whether its role in
37                                 We recommend dexrazoxane as a cardioprotectant for children and adole
38            Given the potential importance of dexrazoxane as a cardioprotectant, we recommend that dex
39 d not vary by dexrazoxane status (12.8% with dexrazoxane at 10 years v 12.2% without; hazard ratio [H
40 included in the analyses; 96 were exposed to dexrazoxane at every anthracycline course, and 918 were
41                               (4) The use of dexrazoxane can be considered in adult patients who have
42 ed cumulative dose of doxorubicin and use of dexrazoxane cardioprotection increased.
43 ane as a cardioprotectant, we recommend that dexrazoxane continue to be used and studied in doxorubic
44 or depletion of topoisomerase IIB (TOP2B) by dexrazoxane could be cardioprotective.
45                         To determine whether dexrazoxane decreases doxorubicin-associated injury of c
46         Amongst various strategies explored, dexrazoxane (DEX) remains the only cardioprotective agen
47                                              Dexrazoxane (DEX)-the only drug approved for its prevent
48                                          The dexrazoxane:doxorubicin dose ratio was 10:1, and the cum
49  Group (POG) studies 9426 and 9425 evaluated dexrazoxane (DRZ) as a cardiopulmonary protectant during
50                                              Dexrazoxane [(DZR), ADR 529, ICRF-187] ameliorates doxor
51                                              Dexrazoxane exerts greater long-term cardioprotective ef
52 nce with cardiac monitoring were similar for dexrazoxane-exposed and -unexposed patients.
53                                              Dexrazoxane-exposed patients had significantly smaller E
54                                              Dexrazoxane-exposed patients had similar 5-year EFS (49.
55 .1 +/- 2.7 years since cancer diagnosis (51% dexrazoxane-exposed; cumulative doxorubicin dose 297 +/-
56 ent-related mortality (TRM) were compared by dexrazoxane exposure.
57 ndom assignment to treatment with or without dexrazoxane given as a bolus infusion immediately before
58 (67-84) for children in the doxorubicin plus dexrazoxane group (p=0.99).
59 orubicin group and in 13% of the doxorubicin-dexrazoxane group before treatment but in 47% and 13%, r
60 up and in 92% of children in the doxorubicin-dexrazoxane group before treatment but in only 48% and 2
61  differ between groups: 76.7% (2.7%) for the dexrazoxane group versus 76.0% (2.7%) for the doxorubici
62                                              Dexrazoxane had no effect on the pharmacokinetics of pac
63                                              Dexrazoxane had no significant effect on the pharmacokin
64 otoxicity and the cardioprotective effect of dexrazoxane, however, is not fully understood.
65                 Cardioprotective activity of dexrazoxane (ICRF-187), the only clinically approved dru
66 ncluded topotecan, irinotecan, etoposide and dexrazoxane (ICRF-187).
67 ng anticancer drugs, the catalytic inhibitor dexrazoxane (ICRF187) and mechanistic poison teniposide
68 results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis p
69 ated with doxorubicin and paclitaxel without dexrazoxane in other trials.
70  on which to base a guideline for the use of dexrazoxane in patients with cardiac risk factors or und
71                               (3) The use of dexrazoxane in the adjuvant setting is not recommended o
72  evidence to make a guideline for the use of dexrazoxane in the treatment of pediatric malignancies,
73                                              Dexrazoxane is a drug used to prevent anthracycline-indu
74 f childhood cancer treated with doxorubicin, dexrazoxane is cardioprotective for at least 5 years.
75                                              Dexrazoxane is not recommended for routine use in breast
76                  Dexrazoxane: (1) The use of dexrazoxane is not routinely recommended for patients wi
77                                              Dexrazoxane is the only cardioprotectant clinically appr
78 on with anthracycline-based chemotherapy and dexrazoxane, its therapeutic benefit remains uncertain.
79                               (2) The use of dexrazoxane may be considered for patients with metastat
80                          Given concerns that dexrazoxane may reduce treatment efficacy, induce second
81  clinical practice guidelines for the use of dexrazoxane, mesna, and amifostine in patients who are n
82 herapy- and radiotherapy-protectant activity-dexrazoxane, mesna, and amifostine-and questions about t
83  the clinical data regarding the activity of dexrazoxane, mesna, and amifostine.
84 orubicin alone (n = 100) or doxorubicin with dexrazoxane (n = 105) during the induction and intensifi
85 despite close monitoring and standard use of dexrazoxane, obliges a change in the dose and/or schedul
86 l be necessary to determine the influence of dexrazoxane on echocardiographic findings at four years
87 e aimed to establish the long-term effect of dexrazoxane on the subclinical state of cardiac health i
88 reexisting HF who received an anthracycline, dexrazoxane or liposomal doxorubicin were used in 78 of
89 nation with an established cardioprotectant, dexrazoxane, or a nitroxide conjugated to a triphenylpho
90 , and some patients received mediastinal RT, dexrazoxane, or mediastinal RT and dexrazoxane.
91 ies, eight occurred in patients who received dexrazoxane (P = .17).
92                                              Dexrazoxane preserved cardiac function without compromis
93                                              Dexrazoxane prevents or reduces cardiac injury, as refle
94                     Subgroup analysis showed dexrazoxane protection (p=0.04) for left ventricular fra
95          Similarly, subgroup analysis showed dexrazoxane protection (p=0.046) for the left ventricula
96                                              Dexrazoxane provides long-term cardioprotection from dox
97                                              Dexrazoxane provides long-term cardioprotection without
98                                              Dexrazoxane reduces cardiac damage during treatment with
99                     The protective effect of dexrazoxane, relative to doxorubicin alone, on left vent
100                                              Dexrazoxane should be considered for cardioprotection du
101                       (6) Patients receiving dexrazoxane should continue to be monitored for cardiac
102 hibiting spore firing, whereas one compound, dexrazoxane, slows infection progression.
103         In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal
104            Overall mortality did not vary by dexrazoxane status (12.8% with dexrazoxane at 10 years v
105 termined the differences and associations by dexrazoxane status.
106 mine overall and cause-specific mortality by dexrazoxane status.
107 s met the inclusion criteria: palifermin and dexrazoxane, three reports (two studies) each; amifostin
108 kemia or lymphoma, after extended follow-up, dexrazoxane use did not seem to compromise long-term sur
109 en receiving mediastinal RT and increases in dexrazoxane use were estimated to offset the increased d
110 2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventricu
111                                              Dexrazoxane was administered at the discretion of treati
112 to 600 mg/m(2) across these five trials, and dexrazoxane was administered uniformly (10:1 mg/m(2) rat
113                                              Dexrazoxane was administered with doxorubicin to minimiz
114 ng adult-aged survivors of childhood cancer, dexrazoxane was associated with a cardioprotective effec
115                                              Dexrazoxane was associated with a reduced risk of having
116                                              Dexrazoxane was cardioprotective and did not compromise
117                                              Dexrazoxane was given as an intravenous bolus before eac
118                  The antiapoptotic action of dexrazoxane was mimicked by the superoxide-dismutase mim
119                                              Dexrazoxane was not associated with an increased risk of
120                                Specifically, dexrazoxane was not associated with deaths from acute my
121                                              Dexrazoxane was started for total doxorubicin dose excee
122           Doxorubicin, cyclophosphamide, and dexrazoxane were administered on days 5 and 6 of the inf
123                           Patients receiving dexrazoxane, which is cardioprotective for anthracycline
124 can be mitigated with the concomitant use of dexrazoxane with anthracycline.
125           Among 1,008 patients (507 received dexrazoxane) with a median follow-up of 12.6 years (rang
126                                              Dexrazoxane (Zinecard, also known as ICRF-187) has been

 
Page Top